IVIG vs plasma exchange: which works best for myasthenic crisis?

NCT ID NCT07532707

Completed Disease control Sponsor: Damascus University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments—intravenous immunoglobulin (IVIG) and plasma exchange (PLEX)—for people experiencing a myasthenic crisis, a severe episode of muscle weakness in myasthenia gravis. Fifty adults were treated with either IVIG or PLEX, and their improvement was measured after 14 days. The goal is to see which treatment is more effective and identify common triggers for these crises.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intravenous Immunoglobulin (IVIG) and Plasma Exchange (PLEX)
What this could lead to: If this study shows one treatment works better, it could help doctors choose the best option for managing severe myasthenic crises.
What could go wrong: This is a small, single-center study with only 50 participants, so results may not apply broadly. It compares two existing treatments, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS (MG) MYASTHENIC CRISIS

Contacts and locations

Locations

Damascus University

Damascus, Syria

More trials for these conditions

Other studies related to the condition(s) this trial covers.